Literature DB >> 14968325

[Modern antimycotics. What the treating physician needs to know].

C Seebacher1.   

Abstract

The treatment of dermatophytoses is a complex process influenced by the properties of the antimycotic and the causative agent as well as by patient-related factors. Both the minimal inhibition concentration and the drug concentration in the infected tissue influence treatment success. Dermatophytes can be present as arthrospores in the skin, nails or hair. Non-proliferating dermatophytes (arthrospores) are less susceptible to antimycotics than proliferating ones, particularly to antibiotics which act through the inhibition of fungal ergosterol synthesis. Non-proliferating dermatophytes do not synthesize ergosterol, a essential component of fugal cell membranes. Also, dermatophytes accumulating in hollow spaces mostly in the nail plate, cannot be reached by antimycotics. The concentration of terbinafine and itraconazole is very high in sebum. This is of importance in the treatment of dermatophytoses localized to in the stratum corneum and in or around the hair. Preadolescent children do not have functioning sebaceous glands; this explains the difficulties in the treatment of pediatric tinea capitis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14968325     DOI: 10.1007/s00105-003-0661-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  23 in total

1.  [RESULTS OF GRISEOFULVIN THERAPY OF ONYCHOMYCOSES. (CONTRIBUTION TO LOCAL THERAPY)].

Authors:  W KRUSPL
Journal:  Z Haut Geschlechtskr       Date:  1965-02-15

Review 2.  The mechanism of action of terbinafine.

Authors:  N S Ryder
Journal:  Clin Exp Dermatol       Date:  1989-03       Impact factor: 3.470

3.  In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin.

Authors:  A Wildfeuer; H P Seidl; I Paule; A Haberreiter
Journal:  Mycoses       Date:  1998 Sep-Oct       Impact factor: 4.377

4.  Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks.

Authors:  J Faergemann; H Zehender; J Denouël; L Millerioux
Journal:  Acta Derm Venereol       Date:  1993-08       Impact factor: 4.437

5.  Bioavailability, skin- and nailpenetration of topically applied antimycotics.

Authors:  G Stüttgen; E Bauer
Journal:  Mykosen       Date:  1982-02

6.  A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region.

Authors:  R Baran; M Feuilhade; P Combernale; A Datry; S Goettmann; P Pietrini; C Viguie; G Badillet; C Larnier; J Czernielewski
Journal:  Br J Dermatol       Date:  2000-06       Impact factor: 9.302

7.  [Limits of brief treatment of onychomycoses].

Authors:  C Seebacher
Journal:  Hautarzt       Date:  1998-09       Impact factor: 0.751

8.  Antifungal activity of the allylamine derivative terbinafine in vitro.

Authors:  G Petranyi; J G Meingassner; H Mieth
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

9.  Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole.

Authors:  P De Doncker; J Decroix; G E Piérard; D Roelant; R Woestenborghs; P Jacqmin; F Odds; A Heremans; P Dockx; D Roseeuw
Journal:  Arch Dermatol       Date:  1996-01

10.  Bioavailability of fluconazole in the skin after oral medication.

Authors:  A Wildfeuer; J Faergemann; H Laufen; G Pfaff; T Zimmermann; H P Seidl; P Lach
Journal:  Mycoses       Date:  1994 Mar-Apr       Impact factor: 4.377

View more
  1 in total

Review 1.  [Onychomycosis: Practical treatment strategies].

Authors:  E G Hasche; M Podda
Journal:  Hautarzt       Date:  2018-09       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.